Court Orders Government to Provide Key AIDS Drug to Pregnant Women

Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.

Court Orders Government to Provide Key AIDS Drug to Pregnant Women

Associated Press (12.14.01) - Friday, December 14, 2001
Dina Kraft

AIDS activists and pediatricians won a landmark lawsuit against the South African government today, forcing it to make a key AIDS drug available to expectant mothers with HIV. AIDS activists who packed the Pretoria court gallery cheered and hugged each other as Judge Chris Botha read a brief judgment stating that the government has to make the drug nevirapine available to all women giving birth in public hospitals.

The government also has to institute a comprehensive program to reduce mother-to-child transmission of HIV nationwide, Botha said. The government was given until March 31, 2002 to report back to the court on how the program - which was to include counseling, HIV testing and follow-up treatment - was being implemented. Dr. Haron Saloojee, one of the pediatricians who filed the lawsuit, called the verdict "a special Christmas present" that could potentially save the lives of 50,000 babies next year.

Some 200 babies are born HIV-positive every day in South Africa, and studies show nevirapine can reduce the transmission of the virus from mother to child during labor by up to 50 percent. But the government had argued that the drug remained unproven. The German drug company Boehringer Ingelheim has offered nevirapine free to developing countries. South Africa has yet to accept the offer, although it is testing the drug at 18 pilot sites. About one in nine South Africans are HIV-positive, and the government's often muddled approach to dealing with AIDS has drawn widespread criticism. Government officials were not immediately available for comment.
011214
AD012169

Copyright © 2001 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.